- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05877651
MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.
May 25, 2023 updated by: SYZ Cell Therapy Co..
A Single-center, Phase I Clinical Study to Evaluate the Safety and Tolerability of Multi-Antigen Stimulated Cell Therapy-I Injection (MASCT-I) in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.
The purpose of this study is to evaluate the safety and tolerability of MASCT-I in patients with metastatic or recurrent solid tumors who failed standard therapy.
Study Overview
Detailed Description
The study is divided into two stages.
The first stage is divided into two groups, both of which adopted 3+3 design.
The first group is given MASCT-I by administration method 1, and the second group is given by method 2. One of the administration method will be used in the second stage according to DLT and adverse events found in the first stage.
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Sun Yat-Sen University Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 1. Age ≥18 years and ≤70 years.
- 2. Written informed consent was obtained.
- 3. Pathologically confirmed solid tumors (including but not limited to soft tissue sarcoma/osteosarcoma, urothelial carcinoma, colorectal cancer), metastatic or recurrent, and failed or intolerant to standard therapy, or lack of effective treatment; Urothelial carcinoma including renal pelvic carcinoma, bladder cancer, ureteral carcinoma or urethral carcinoma.
- 4. ECOG performance status of 0-1.
- 5. Estimated life expectancy ≥ 6 months.
- 6. Patients must have at least one measurable lesion defined by RECIST 1.1.
- 7. At least 4 weeks after the end of the last anti-tumor treatment before the 1st apheresis;
8. Patients with organ function as defined below (any blood components and growth factors are not allowed within 14 days before apheresis) :
- Leukocytes ≥ 3.0 x 10^9/L;
- Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L;
- Platelets ≥ 100 x 10^9/L;
- Hemoglobin ≥ 90g/L;
- Serum albumin ≥ 3.0g/dL;
- Total bilirubin≤1.5×ULN; ALT/AST≤1.5×ULN (patients with liver metastasis or liver cancer, ≤5×ULN);
- Creatinine clearance ≥50mL/min (Cockcroft -Gault formula);
- Serum urea nitrogen/urea and creatinine ≤1.5×ULN (patients with urothelium carcinoma, ≤2.5×ULN);
- 9. Patients with potential fertility need to use a medically approved contraceptive measure (such as intrauterine device, contraceptive pill or condom) during the study treatment period and within 3 months after the end of the study treatment period; The serum or urine HCG test must be negative within 7 days before the study was included; And must be non lactating.
Exclusion Criteria:
- 1. Organ transplanters;
- 2. Allergic to sodium citrate or human albumin;
- 3. Patients who have undergone major surgery within 30 days before 1st apheresis (according to the investigator's definition);
- 4. Patients with uncontrolled cardiac symptoms or diseases, such as: (1) heart failure of NYHA class 2 or higher (2) unstable angina pectoris (3) myocardial infarction within 1 year (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;
- 5. Patients have received radiotherapy, hormonotherapy, surgery or targeted therapy, or immunotherapy, and less than 4 weeks before the 1st apheresis;
- 6. Patients have active infection or fever of unknown cause during screening and before 1st apheresis is more than 38.5 degrees (patients with fever caused by cancer is eligible for enrollment according to investigator's judgement);
- 7. Patients have clinically symptomatic central nervous system metastases (e.g., brain edema, need for hormonal intervention, or progression of brain metastases). Patients have previously received treatment for brain or leptomeningeal metastases were eligible if they have been clinically stable for at least 2 months and stopped systemic hormone therapy (dose >10mg/day prednisone or other therapeutic hormones) for more than 2 weeks;
- 8. Patients were using immunosuppressive agents or systemic or absorbable local hormones to achieve immunosuppressive purposes (dose > 10mg/day prednisone or other therapeutic hormones) and were still using them within 2 weeks before enrollment.
- 9. Systematic or long-term use of immunomodulators such as interferon, thymosin and immunosuppressive drugs such as adrenocorticosteroids in half a year; Systematic or long-term use of immunomodulators for more than three months and immunosuppressive drugs for more than one month;
- 10. Patients have received MASCT or other cellular immunotherapy in the past 1 year;
- 11. Patients have any active autoimmune disease or history of autoimmune disease;
- 12. Patients with other malignant tumors (except cured skin basal cell carcinoma, thyroid carcinoma and cervical carcinoma in situ) within 5 years before enrollment or at enrollment;
- 13. Patients with active tuberculosis;
- 14. Known active hepatitis B virus (except for liver cancer) or hepatitis C virus infection, and/or HIV or syphilis infection;
- 15. Patients are receiving other systemic antineoplastic therapy or currently enrolled in other clinical study, or have participated in an investigational drug trial or used an investigational device within 4 weeks before 1st apheresis, or have not recovered from toxicity of the last treatment (adverse events should be grade 1 or less according to CTCAE criteria or return to the baseline before treatment);
- 16. According to investigator's judgement, those who are not suitable for enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MASCT-I injection
|
The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events and serious adverse events related to MASCT-I
Time Frame: 8 weeks
|
Assessed by CTCAE V5.0
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events and serious adverse events related to MASCT-I
Time Frame: 2 years
|
All adverse events and serious adverse events related to MASCT-I during the study
|
2 years
|
Immune response to tumor-associated antigens
Time Frame: 2 years
|
Measured by enzyme linked immunospot assay
|
2 years
|
Concentration of Cytokines (IFNγ、IL2、IL4、IL6、IL10 and TNF)
Time Frame: 2 years
|
Measured by flow cytometry or other methods
|
2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: 2 years
|
The length of time from enrollment until the time of progression of disease
|
2 years
|
Objective Response Rate (ORR)
Time Frame: 2 years
|
Percentage of patients with PR and CR in the total number of patients.
|
2 years
|
Disease Control Rate (DCR)
Time Frame: 2 years
|
Disease control rate is defined as the number of patients with a best overall response of complete response (CR), partial response (PR), or stable disease (SD) based on RESIST v1.1 criteria
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ruihua Xu, Doctor, Sun Yat-sen University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 21, 2020
Primary Completion (Actual)
October 15, 2021
Study Completion (Actual)
October 15, 2021
Study Registration Dates
First Submitted
May 9, 2023
First Submitted That Met QC Criteria
May 17, 2023
First Posted (Actual)
May 26, 2023
Study Record Updates
Last Update Posted (Actual)
May 30, 2023
Last Update Submitted That Met QC Criteria
May 25, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MASCT-I-2001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Alphamab (Australia) Co Pty Ltd.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsAustralia
Clinical Trials on MASCT-I injection
-
The First People's Hospital of LianyungangHengrui Yuanzheng Bio-Technology Co., Ltd.UnknownSolid Tumors
-
Sun Yat-sen UniversityThe First Affiliated Hospital of Guangzhou Medical University; Sixth Affiliated...RecruitingHepatectomy | Primary Liver Cancer | Immunotherapy | Radiofrequency AblationChina
-
The First People's Hospital of LianyungangHengrui Yuanzheng Bio-Technology Co., Ltd.Unknown
-
SYZ Cell Therapy Co..Peking University Cancer Hospital & InstituteUnknownAdvanced Gastric CancerChina
-
HRYZ Biotech Co.Not yet recruitingLeiomyosarcoma | Fibrosarcoma | Liposarcoma | Angiosarcoma | Synovial Sarcoma | Endometrial Stromal Sarcoma | Undifferentiated Pleomorphic Sarcoma | Epithelioid Sarcoma | Desmoplastic Small Round Cell Tumor | Malignant Peripheral Nerve Sheath Tumors | Pleomorphic RhabdomyosarcomaChina
-
HRYZ Biotech Co.Recruiting
-
Hospital of the Ministry of Interior, Kielce, PolandNot yet recruitingTemporomandibular Joint Disorders | Temporomandibular Joint Pain
-
Tishreen UniversityCompletedOrthodontic Pathological Resorption of External RootSyrian Arab Republic
-
Cellectar Biosciences, Inc.Withdrawn
-
Tomsk National Research Medical Center of the Russian...Uppsala University; The Shemyakin and Ovchinnikov Institute of Bioorganic ChemistryEnrolling by invitationOvarian Cancer | Lung CancerRussian Federation